CPA
ALDX icon

Capital Performance Advisors’s Aldeyra Therapeutics ALDX Stock Holding History

Capital Performance Advisors’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-17
Closed -$92 – 260
2024
Q3 		$92 Buy
+17
New +$81 ﹤0.01% 2713

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Capital Performance Advisors's ALDX Position: Q4 2024 in Review

Capital Performance Advisors sold out of Aldeyra Therapeutics (ALDX) in Q4 2024, closing a stake of 17 shares — an estimated $92 sold.

Capital Performance Advisors first reported a position in ALDX in Q3 2024 and held it in 1 quarter. The position peaked at $92 in Q3 2024. 118 funds tracked by Wall St. Rank hold ALDX as of Q4 2024.

  • Capital Performance Advisors reported no remaining Aldeyra Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 17 Aldeyra Therapeutics shares in Q4 2024, an estimated $92.
  • Capital Performance Advisors first reported a position in Aldeyra Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Aldeyra Therapeutics position peaked at $92 in Q3 2024.
  • 118 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.